at Zacks.com (Thu, 10:51AM)
Celgene (CELG -4.3%) gets FDA approval for its supplemental new drug application for Revlimid to treat mantle cell lymphoma. The drug is already cleared for multiple myeloma, another white blood cell cancer. Analysts estimate the drug could generate around $5.9B in sales in 2016.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Thu, 8:59AM)
at Zacks.com (Tue, 4:45PM)
at Zacks.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs